We are live on ! Find out more
KLDO

Kaleido Biosciences, Inc. Common Stock

Delisted

KLDO was delisted on the 14th of April, 2022.

60 hedge funds and large institutions have $213M invested in Kaleido Biosciences, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 5

41% more capital invested

Capital invested by funds: $151M → $213M (+$62.3M)

33% more funds holding

Funds holding: 4560 (+15)

33% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 12

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
60
Holders Change
+15
Holders Change %
+33.33%
% of All Funds
1.23%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
20
Increased
16
Reduced
12
Closed
5
Calls
Puts
Net Calls
Net Calls Change

KLDO Hedge Fund Activity: Q2 2020 in Review

60 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Kaleido Biosciences, Inc. Common Stock (KLDO) for Q2 2020, worth a combined $213M — up 41% from $151M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new KLDO positions and 5 closed out — a net gain of 15 holders — while 16 added to existing stakes and 12 trimmed.

The largest buyer was Flagship Pioneering, adding an estimated $13.4M. The largest seller was Victory Capital Management, cutting an estimated $1.18M.

  • 60 institutional investors held Kaleido Biosciences, Inc. Common Stock (KLDO) as of Q2 2020, up from 45 in Q1 2020.
  • Funds reported $213M of Kaleido Biosciences, Inc. Common Stock stock for Q2 2020, up 41% quarter-over-quarter.
  • 20 funds opened new Kaleido Biosciences, Inc. Common Stock positions in Q2 2020 and 5 closed out, a net change of +15 holders.
  • The largest Kaleido Biosciences, Inc. Common Stock buyer in Q2 2020 was Flagship Pioneering, an estimated $13.4M added.
  • The largest Kaleido Biosciences, Inc. Common Stock seller in Q2 2020 was Victory Capital Management, an estimated $1.18M sold.

Based on aggregated 13F filings for Q2 2020.